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Purpose of the study
PR prolongation has been reported with HIV protease
inhibitors such as atazanavir. We evaluated the potential
for PR prolongation with LPV/r and RTV.
Methods
Phase I, multiple-dose, open-label, placebo-controlled,
randomized study conducted according to a crossover
design. Study drugs were dosed for 3 days to allow for
maximal exposure, as RTV-mediated CYP3A4 inhibition
is complete and induction is minimal. LPV/r was dosed at
400/100 mg BID and at supratherapeutic 800/200 mg
BID. RTV was dosed at 400 mg BID. Digital EKGs and
pharmacokinetic samples were obtained on study Day 3.
Absolute PR interval on Day 3 and change from baseline
were evaluated. Exposure-PR response modeling was per-
formed.
Summary of results
Substantially higher LPV (30–50% for 400/100 mg BID
and 3-fold for 800/200 mg BID) and RTV (2-fold) concen-
trations were achieved on Study Day 3 compared to his-
torical steady-state values of LPV/r 400/100 mg BID and
RTV 600 mg BID. Mean PR changes from baseline ranged
from 11.6–24.4 msec (LPV/r 400/100 mg BID), 22.0–
31.2 msec (LPV/r 800/200 mg BID) and 11.0–24.0 msec
(RTV 400 mg BID), all p < 0.0001 compared to placebo.
No subject had a PR interval greater than 286 msec. No
subject experienced 2nd or 3rd degree atrioventricular
block.
Conclusion
Based on the exposure-response model, it is estimated
that the mean PR effect plateaus and has reached its max-
imum with the supratherapeutic 800/200 mg BID dose. At
steady state, LPV/r is expected to produce clinically insig-
nificant increases in PR interval of 18 to 20 msec and low
dose ritonavir (100–400 mg daily) is expected to prolong
PR by 4.8 to11.6 msec. LPV/r and RTV do not result in
clinically significant increases in PR interval. However,
this effect should be considered when co-administering
LPV/r or RTV with other drugs known to prolong PR inter-
val or in patients with co-morbid conditions.
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